Karyopharm Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $44.6M
- Price
- $1.84
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.12%
- Volume
- 865.6K
About
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Quick stats
Shares outstanding22.7M
Computed float18.0M
Float / shares79.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001503802
Websitehttps://www.karyopharm.com
AI Summary
AI-generated1/33
majormixedearnings
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Karyopharm reported Q2 2026 total revenue of $33.4 million, down from $37.9 million in the prior year, while U.S. XPOVIO net product revenue increased to $30.8 million.
The company remains on track for an August sNDA submission for selinexor in myelofibrosis but disclosed that the Phase 3 XPORT-EC-042 trial in endometrial cancer did not meet its primary endpoint.
Management issued a going concern warning, stating current cash of $65.4 million funds operations only into September 2026, and a pending debt payment could trigger a liquidity covenant breach without new financing.
Red flags
- Substantial doubt exists regarding ability to continue as a going concern
- Cash runway extends only to September 2026
- Potential liquidity covenant breach if $15.8M debt payment is made
- Phase 3 XPORT-EC-042 trial failed to meet primary endpoint